IP Library › Granted Patent US 12,257,027
Granted Patent B2
US 12,257,027 · App. 17/401,866 · Granted Mar 25, 2025

Transcutaneous organ function measurement

Inventors: Ralf Heinrich (Schwegenheim, DE); Johannes Pill (Leimen, DE); Sabine Neudecker (Ludwigshafen, DE); Daniel Schock-Kusch (Mannheim, DE); Juergen Guenther (Schriesheim, DE); Stefan Koenig (Lorsch, DE); Jochen Friedemann (Altrip, DE)
Assignee: MEDIBEACON INC.
A61B5/0071A61B5/1455A61B5/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,027
App. No.
17/401,866
Granted
Mar 25, 2025
Kind
B2
Abstract

The present invention relates to a method for determining an organ function in a subject, comprising the steps of: providing a first concentration-time curve obtained by transcutaneously measuring in a body fluid at a first position background fluorescence in at least one first time point and fluorescence of an indicator compound in at least a second, a third, a fourth, a fifth, and a sixth time point; providing a second concentration curve obtained by transcutaneously measuring in a body fluid at a second position background fluorescence in at least one seventh time point and fluorescence of an indicator compound in at least a eighth, a ninth, a tenth, an eleventh, and a twelfth time point; fitting the first and the second concentration curve into a kinetic model representing at least four diffusion compartments; and thereby determining an organ function in a subject. The invention further relates to a device for determining an organ function according to the method of the present invention, said device comprising a first sensor for transcutaneously measuring fluorescence of an indicator at a first position, a second sensor for transcutaneously measuring fluorescence of an indicator at a second position; and a data processing unit for fitting the values obtained by the sensors into a kinetic model of one of the preceding claims. The present invention also relates to a kit comprising a device of the present invention and an indicator compound, as well as to a computer or computer network comprising at least one processor, wherein the computer or computer network is adapted to perform the method according to the present invention.

Claims (31)

1. A device configured to determine an organ function in a subject in need thereof, said device comprising:

a first sensor configured to (i) detect a first set of photons emitted by an indicator compound in a first body fluid at a first position on the subject, and (ii) transcutaneously measure, based on the first set of photons, a first concentration-time curve in the first body fluid;

a second sensor configured to (i) detect a second set of photons emitted by the indicator compound in a second body fluid at a second position on the subject, and (ii) transcutaneously measure, based on the second set of photons, a second concentration-time curve in the second body fluid; and

a data processing unit configured to fit values associated with the first and second concentration-time curves into a kinetic model,

wherein the first body fluid and the second body fluid of the subject may be the same or different, and said first sensor and said second sensor are operatively linked in that the data processing unit of the device is configured to bring together results of the transcutaneous measurements performed by the first sensor and the second sensor and fit the transcutaneous measurements into the kinetic model to determine the organ function.

2. The device according to claim 1 , wherein the first sensor or the second sensor configured to detect the first set of photons or the second set of photons emitted by the indicator compound upon irradiation with an excitation light.

3. The device according to claim 1 , wherein the first sensor or the second sensor comprises a source of excitation light.

4. The device according to claim 1 , wherein the first sensor or the second sensor is in a form of a sensor plaster.

5. The device according to claim 1 , wherein the first sensor and the second sensor are separate devices.

6. The device according to claim 1 , wherein the first sensor and the second sensor are comprised in one casing.

7. The device according to claim 1 , wherein the device is configured to output unprocessed data.

8. The device according to claim 1 , wherein the device is configured to output processed data.

9. The device according to claim 1 , wherein the device further comprises a data storage unit comprising at least reference values of total plasma volume correlated to body mass.

10. The device according to claim 1 , wherein the device is configured to calculate a glomerular filtrate rate (GFR).

11. The device according to claim 1 , wherein the device is configured to calculate a glomerular filtrate rate (GFR) from a result of fitting the first concentration-time curve and the second concentration-time curve to the kinetic model in combination with a plasma volume estimate derived from a body mass of the subject.

12. The device according to claim 1 , wherein the first body fluid and the second body fluid of the subject are each individually selected from the group consisting of blood, plasma, interstitial fluid, a local interstitium at a position of measurement, and combinations thereof.

13. A method for determining an organ function in a subject, the method comprising:

administering a fluorescent indicator compound to the subject;

detecting a first set of photons emitted by the fluorescent indicator compound in a body fluid at a first position on the subject;

detecting a second set of photons emitted by the fluorescent indicator compound in the body fluid at a second position on the subject;

measuring transcutaneously, based on the first set of photons, a first concentration-time curve at the first position on the subject, wherein said first concentration-time curve comprises (i) at least one data point collected prior to administering the fluorescent indicator compound to the subject as a first background time point, and (ii) at least five data points collected after administering the fluorescent indicator compound to the subject;

simultaneously measuring transcutaneously, based on the second set of photons, a second concentration-time curve at the second position on the subject, wherein said second concentration-time curve comprises (i) at least one data point collected prior to administering the fluorescent indicator compound to the subject as a second background time point, and (ii) at least five data points collected after administering the fluorescent indicator compound to the subject;

measuring a concentration of the fluorescent indicator compound in the body fluid within a time frame of the first transcutaneous measurement and the second transcutaneous measurement; and

fitting the first concentration-time curve, the second concentration-time curve, and the concentration of the fluorescent indicator compound in the body fluid into a kinetic model representing two or three or four diffusion compartments to determine the organ function, wherein the diffusion compartments are selected from the group consisting of plasma, interstitial fluid, local interstitium at the position of the measuring, and distribution.

14. The method according to claim 13 , wherein the kinetic model represents four diffusion compartments.

15. The method according to claim 13 , wherein the administering is performed orally, intraarterially, intravenously, or as a bolus injection.

16. The method according to claim 13 , wherein the administering comprises administering the fluorescent indicator compound to the bloodstream of the subject.

17. The method according to claim 13 , wherein the organ function is a glomerular filtration rate (GFR).

18. The method according to claim 13 , wherein the measuring the concentration of the fluorescent indicator compound in the body fluid within the time frame of the first transcutaneous measurement and the second transcutaneous measurement comprises taking a blood sample from the subject.

19. The method according to claim 13 , wherein the measuring the concentration of the fluorescent indicator compound in the body fluid within the time frame of the first transcutaneous measurement and the second transcutaneous measurement comprises taking a blood sample from the subject to determine the concentration of the fluorescent indicator compound in a plasma of the subject.

20. The method according to claim 13 , wherein the body fluid of the subject is selected from the group consisting of blood, plasma, interstitial fluid, a local interstitium at a position of measurement, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2025
From: HEINRICH, RALF; PILL, JOHANNES; NEUDECKER, SABINE; SCHOCK-KUSCH, DANIEL; GUENTHER, JUERGEN; KOENIG, STEFAN; FRIEDEMANN, JOCHEN
To: MEDIBEACON INC.
Reel/Frame 069820/0979 →
Priority Claims (1)
EP 13189703 · Oct 22, 2013 · regional
Continuity (4)
Continuation 16289529 · Feb 28, 2019
Continuation 15030727
Related Publication 20220022753A1 · Jan 27, 2022
Related Publication 20230132361A9 · Apr 27, 2023
References Cited (62)
US 4301140A · Frank et al. · 1981 [cited by applicant]
US 6440389B1 · Rabito · 2002 [cited by applicant]
US 20030236452A1 · Melker et al. · 2003 [cited by applicant]
US 20040022730A1 · Hein et al. · 2004 [cited by applicant]
US 20040210280A1 · Liedtke · 2004 [cited by applicant]
US 20060020216A1 · Oishi et al. · 2006 [cited by applicant]
US 20060095102A1 · Perez · 2006 [cited by applicant]
US 20070237678A1 · Roesicke et al. · 2007 [cited by applicant]
US 20080281173A1 · Esenaliev et al. · 2008 [cited by applicant]
US 20100121170A1 · Rule · 2010 [cited by applicant]
US 20110191087A1 · Lehrach et al. · 2011 [cited by applicant]
US 20110201940A1 · Wang et al. · 2011 [cited by applicant]
US 20110230739A1 · Gretz et al. · 2011 [cited by applicant]
US 20120123229A1 · Butterfield et al. · 2012 [cited by applicant]
US 20120123247A1 · Hu et al. · 2012 [cited by applicant]
US 20130116512A1 · Imran · 2013 [cited by applicant]
US 20130116518A1 · Wang et al. · 2013 [cited by applicant]
US 20150306486A1 · Logan et al. · 2015 [cited by applicant]
DE 10023051A1 · 2001 [cited by applicant]
DE 102004048864A1 · 2006 [cited by applicant]
JP 2008538316A · 2008 [cited by applicant]
JP 2011501681A · 2011 [cited by applicant]
WO 9931183A1 · 1999 [cited by applicant]
WO 200185799A1 · 2001 [cited by applicant]
WO 200632441A2 · 2006 [cited by applicant]
WO 2010020673A2 · 2010 [cited by applicant]
WO 2010093635A2 · 2010 [cited by applicant]
International Preliminary Report on Patentability in corresponding International Application No. PC/EP2014/072420, dated Jan. 21, 2016. [cited by applicant]
Cussler, “Diffusion: Mass Transfer in Fluid Systems”, Cambridge University press, Published 1997, Third Edition. [cited by applicant]
Frennby et al., “Contrast Media as Markers of GFR”, 2002, European Radiology, Published May 16, 2001, pp. 475-484, vol. 12, No. 2, Springer International, Berlin, DE. [cited by applicant]
Mikhail et al., “Rational Approach to Select Small Peptide Molecular Probes Labeled with Fluorescent Cyanine Dyes for in Vivo Optical Imaging”, Biochemistry, Published Apr. 5, 2011, pp. 2691-2700, vol. 50, No. 13. [cited by applicant]
Pais et al., “High-sensitivity, Disposable Lab-on-a-Chip with Thin-Film Organic Electronics for Fluorescence Detection”, Lab on a Chip, Published Mar. 20, 2008, pp. 794-800, vol. 8. [cited by applicant]
Pill et al., “Direct Fluorometric Analysis of a Newly Synthesised Fluorescein-Labelled Marker for Glomerular Filtration Rate”, Analytical and Bioanalytical Chemistry, Published May 2005, pp. 59-64, vol. 382, No. 1. [cited by applicant]
Pill et al., “Fluorescein-Labeled Sinistrin as Marker of Glomerular Filtration Rate”, European Journal of Medicinal Chemistry, Published Oct. 2005, pp. 1056-1061, vol. 40, No. 10. [cited by applicant]
Margouleff, “Blood vol. Determination, A Nuclear Medicine Test in Evolution”, Clinical Nuclear Medicine, Published Jul. 2013, pp. 534-537, vol. 38, No. 7. [cited by applicant]
Probst et al., “Gender Differences in the Blood vol. of Conscious Sprague-Dawley Rats”, Journal of the American Association for Laboratory Animal Science, Published Mar. 1, 2006, pp. 49-52, vol. 45, No. 2. [cited by applicant]
Qi et al., “Serial Determination of Glomerular Filtration Rate in Conscious Mice Using FITC-Inulin Clearance”, American Journal of Physiology—Renal Physiology, Published Mar. 1, 2004, pp. F590-F596, vol. 286, No. 3. [cited by applicant]
Schock-Kusch et al., “Transcutaneous Measurement of Flomerular Filtration Rate Using FITC-Sinistrin in Rats”, Nephrology Dialysis Transplantation, Published Oct. 2009, pp. 2997-3001, vol. 24, No. 10. [cited by applicant]
Schock-Kusch et al., “Online Feedback-Controlled Renal Constant Infusion Clearances in Rats”, Kidney International, Published Aug. 1, 2012, pp. 314-320, vol. 82, No. 3. [cited by applicant]
Schock-Kusch et al., “Transutaneous Assessment of Renal Function in Conscious Rats with a Device for Measuring FITC-Sinistrin Disappearance Curves”, Kidney International, Published Jun. 1, 2011, pp. 1254-1258, vol. 79, … [cited by applicant]
Wang et al., “Transgenic Overexpression of GLUTI in Mouse Glomeruli Produces Renal Disease Resembling Diabetic Glomerulosclerosis”, American Journal of Physiology—Renal Physiology, Published Jul. 1, 2010, pp. F99-F111, … [cited by applicant]
Wang et al., “Rapid Diagnosis and Quantification of Acute Kidney Injury Using Fluorescent Ratio-Metric Determination of Glomerular Filtration Rate in the Rat”, American Journal of Physiology—Renal Physiology, Published … [cited by applicant]
Friedemann, “Development of a Pharmokinetic Model to Describe the Distribution and Excretion Kinetics of a Renal Marker Using Transcutaneously Obtained Data in Rats”, Dissertation from University Heidelberg, Published 2… [cited by applicant]
Pharsight, “WinNonlin User's Guide”, Version 5.3, Pharsight Corporation, 710 pages. [cited by applicant]
Brenner et al., “Quantitative Importance of Changes in Postglomerular Colloid Osmotic Pressure in Mediating Glomerulotubular Balance in the Rat,” The Journal of Clinical Investigation, vol. 52, (1973), pp. 190-197. [cited by applicant]
Chinen et al., “Fluorescence-Enhanced Europium-Diethylenetriaminepentaacetic (DTPA)-Monoamide Complexes for the Assessment of Renal Function,” J. Med. Chem., vol. 51, (2008), pp. 957-962. [cited by applicant]
Dean et al., “Inulin, Diodone, Creatinine And Urea Clearances In Newborn Infants,” J. Physiol., vol. 106, (1947), pp. 431-439. [cited by applicant]
Debreczeny et al., “Transdermal Optical Renal Function Monitoring in Humans: Development, Verification, and Validation of a Prototype Device,” Journal of Biomedical Optics, vol. 23, No. 5, (May 2018), pp. 057003-1-05700… [cited by applicant]
Friedman et al., “A comparison of the renal clearances of allantoin and inulin in man,” Fed. Proc., vol. 7, No. 1 Pt 1, (1948), 1 page. [cited by applicant]
Gregory et al., “Studies on Hypertension; Effect of Lowering the Blood Pressures of Hypertensive Patients by High Spinal Anesthesia on the Renal Function as Measured by Inulin and Diodrast Clearances,” Arch. Intern. Med… [cited by applicant]
Levin et al., “The Effect of Chronic Anemia on Renal Function as Measured by Inulin and Diodrast Clearances,” Proc. Annu. Meet. Cent. Soc. Clin. Res. U. S., vol. 20, (1947), 3 pages. [cited by applicant]
Nagpal et al., “Combined Fluorescein, Indocyanine angiography and Optical Coherent Tomography Using Spectralis,” Rajasthan Journal of Ophthalmology, (2011), 8 pages. [cited by applicant]
Navar et al., “Distal Tubular Feedback in the Autoregulation of Single Nephron Glomerular Filtration Rate,” J. Clin. Invest., vol. 53, (1974), pp. 516-525. [cited by applicant]
Nicholson et al., “Renal Function as Affected by Experimental Unilateral Kidney Lesions : I. Nephrosis Due to odium Rartrate,” J. Exp. Med., vol. 68, (1938), pp. 439-456. [cited by applicant]
Pill et al., “Fluorescein-labeled Sinistrin as Marker of Glomerular Filtration Rate,” European Journal of Medicinal Chemistry, vol. 40, (2005), pp. 1056-1061. [cited by applicant]
Poujeol et al., “Glomerular Filtration Rate and Microsphere Distributions in Single Nephron of Rat Kidney,” Pflugers Arch., vol. 357, (1975), pp. 291-301. [cited by applicant]
Robson et al., “The Determination of the Renal Clearance of Inulin in Man,” Q. J. Exp. Physiol., vol. 35, (1949), pp. 111-134. [cited by applicant]
Schock-Kusch et al., “Transcutaneous measurement of glomerular filtration rate using FITC-sinistrin in rats,” Nephrol Dial Transplant, vol. 24, (2009), pp. 2997-3001. [cited by applicant]
Shannon et al., “The Renal Excretion of Inulin and Creatinine by the Anaesthetized Dog and the Pump-Lung-Kidney Preparation”, J. Physiol., vol. 98, (1940), pp. 97-108. [cited by applicant]
Yu et al., “Rapid determination of renal filtration function using an optical ratiometric imaging approach,” Am. J. Physiol. Renal. Physiol., vol. 292, (2007), pp. F1873-F1880. [cited by applicant]
International Search Report received for PCT Patent Application No. PCT/US2019/013784, mailed on May 7, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/013784, mailed on Jul. 30, 2020, 8 pages. [cited by applicant]